Table 2.

Week 6 change from double-blind baseline in efficacy measures.

	LS mean (SE)	LSMD (95% CI)	Effect size	p-value
PANSS total
Lurasidone 40 mg	−22.0 (1.6)	−9.4 (−13.5, −5.2)	0.53	<0.001
Lurasidone 80 mg	−22.7 (1.6)	−10.1 (−14.3, −5.9)	0.57	<0.001
Lurasidone 120/160 mg	−28.7 (2.6)	−16.1 (−22.0, −10.1)	0.90	<0.001
Placebo	−12.6 (1.5)
PANSS positive subscale
Lurasidone 40 mg	−7.5 (0.5)	−3.7 (−5.0, −2.4)	0.65	<0.001
Lurasidone 80 mg	−7.8 (0.5)	−4.0 (−5.3, −2.6)	0.70	<0.001
Lurasidone 120/160 mg	−9.8 (0.9)	−5.9 (−7.9, −4.0)	1.05	<0.001
Placebo	−3.8 (0.5)
PANSS negative subscale
Lurasidone 40 mg	−4.7 (0.5)	−2.1 (−3.3, −0.9)	0.42	<0.001
Lurasidone 80 mg	−4.7 (0.4)	−2.1 (−3.3, −0.9)	0.42	<0.001
Lurasidone 120/160 mg	−5.6 (0.8)	−3.0 (−4.8, −1.3)	0.60	<0.001
Placebo	−2.6 (0.4)
PANSS general psychopathology subscale
Lurasidone 40 mg	−9.6 (0.8)	−3.3 (−5.4, −1.2)	0.37	0.002
Lurasidone 80 mg	−10.1 (0.8)	−3.8 (−5.9, −1.7)	0.42	<0.001
Lurasidone 120/160 mg	−13.4 (1.4)	−7.1 (−10.2, −4.1)	0.80	<0.001
Placebo	−6.3 (0.8)
CGI-S
Lurasidone 40 mg	−1.13 (0.10)	−0.52 (−0.76, −0.27)	0.51	<0.001
Lurasidone 80 mg	−1.10 (0.10)	−0.49 (−0.73, −0.25)	0.48	<0.001
Lurasidone 120/160 mg	−1.60 (0.16)	−0.98 (−1.33, −0.64)	0.96	<0.001
Placebo	−0.62 (0.09)
PANSS responders (≥30% improvement)	Responder rate (%; LOCF-endpoint)	NNT	Odds ratio (95% CI)	p-value
Lurasidone 40 mg	49.3	6	2.5 (1.6, 4.1)	<0.001
Lurasidone 80 mg	51.4	5	2.7 (1.7, 4.3)	<0.001
Lurasidone 120/160 mg	55.0	4	2.2 (1.1, 4.3)	0.025
Placebo	30.0

Notes: Sample size: lurasidone 40 mg (n = 151), 80 mg (n = 145), 120/160 mg (n = 60); placebo (n = 180).

Abbreviations: CGI-S, Clinical Global Impression–Severity Scale; LSMD (95% CI), LS mean difference in Week 6 change scores for lurasidone versus placebo (with 95% confidence intervals); NNT, number needed to treat; PANSS, Positive and Negative Syndrome Scale.